Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review

Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review

Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD). Although existing studies have investigated the efficacy of ESK in the 4-week induction phase, our knowledge about long-term ESK efficacy remains poor. The aim of this systematic revie...

Full description

Bibliographic Details
Main Authors: Enrico Capuzzi, Alice Caldiroli, Martina Capellazzi, Ilaria Tagliabue, Matteo Marcatili, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli, Antonios Dakanalis
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:International Journal of Molecular Sciences
Subjects:
treatment-resistant depression
esketamine
clinical trials
continuation
systematic review
Online Access:https://www.mdpi.com/1422-0067/22/17/9338

Internet

https://www.mdpi.com/1422-0067/22/17/9338

Similar Items